Scimitar Equity Blog

 Aastrom is a leader in regenerative medicine developing autologous cell products for the treatment of severe, chronic cardiovascular diseases. ASTM’s proprietary Tissue Repair Cell (TRC) technology expands the numbers of stem and early progenitor cells from a small amount of bone marrow collected from the patient.

Read more…

                                  Referencing our blogs on: Opexa Therapeutics (12/2), Geron Corp (11/30), StemCells (11/18) Cytori Therapeutics (11/17), Aastrom Biosciences 11/16), Advanced Cell Technology (11/23) and Athersys  (11/16). A new era in embryonic stem cell research is evolving as the National Institutes of Health (NIH) approved 13 batches of the master cells to study – using taxpayer dollars – with dozens more in the pipeline. Read more…

Opexa Therapeutics, Inc. is develops of patient-specific cellular therapies for the treatment of autoimmune diseases.  Market Opportunity: The name Multiple Sclerosis (MS) simply refers to the buildup of scar tissue in the brain and spinal cord. An unpredictable disease of the central nervous system, multiple sclerosis can range from being relatively benign to somewhat disabling to devastating as communication between the brain and other parts of the body is disrupted. Read more…

GERN is developing bio pharmaceuticals for the treatment of cancer and chronic degenerative diseases including spinal cord injury, heart failure and diabetes.  (www.geron.com) Focus: Geron develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening.  Read more…

 StemCells Inc,  a clinical-stage biotechnology company focuses on commercialization of products derived from stem cell technologies. STEM is targeting diseases of the central nervous system and liver. StemCells also markets specialty cell culture media products under the brand SC Proven ® and is developing its cell-based technologies for use in drug screening and drug development.  (www.stemcellsinc.com) Read more…

Updating our Cytori Therapeutics blogs of 11/3/09 and 11/10/09 …  Completion of the RESTORE 2 study is – IMPORTANT – because it lays the foundation for – reimbursement – in the EU;  CYTX is already – CE Marked – for certain uses in the EU! Read more…

Cytori Therapeutics is developing treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. CYTX engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. (http://www.cytoritx.com ) Read more…

Athersys (ATHX) is a bio-pharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. ATHX is developing MultiStem, a patented adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. (www.athersys.com) Read more…

Cytori Therapeutics is developing treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. CYTX engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. (http://www.cytoritx.com ) Read more…

Referencing our previous 4 blogs; I thought I would back-up my posts with a few stem cell topic definitions (3 of 3 blogs); these were  extrapolated from various websites and a sector report I have put together as well as excerpts from the International Society for Stem Cell Research.

Are some kinds of stem cells better than others?

• Read more…